

### **H.G.F. License Contract**

*Tokyo, London 5 October, 2005* –Sosei Co. Ltd. [4565, Tokyo Stock exchange MOTHERS index] acquired the license for the intellectual property rights related to the hepatocyte growth factor (HGF), identified by Professor Toshikazu Nakamura, of Osaka University School of Medicine. These intellectual property rights were sub-licensed to Sumitomo Pharmaceuticals Company (now Dainippon Sumitomo Pharma Co., Ltd.).

Some of these related intellectual property rights act as a basic patent for using the HGF gene in gene therapy. A transfer of intellectual property rights has been made from Dainippon Sumitomo Pharma to MedGene Bioscience Co., Ltd (now AnGes MG, Inc.). Following this transfer Sosei now has the right to obtain part of the compensation which Dainippon Sumitomo Pharma will receive from AnGes MG, Inc.

-end-

### **Notes to Editors:**

#### **About Sosei:**

Sosei Co. Ltd., founded in 1990 by Shinichi Tamura, the former CEO of Genentech Japan, is a leading Japanese biopharmaceutical company with significant expertise in drug development. It enriches its core product pipeline by in-licensing compounds from Western and Japanese companies, by its distinctive Drug Reprofiling Platform® (DRP®) and through new molecular entity (NME) research programmes in collaboration with biopharmaceutical companies and universities both in Japan and the West.

Sosei is also developing its own sales and marketing organization in Japan. The company is capitalising on its extensive global network established over the past 10 years in its successful technology transfer business. For further information on Sosei, please refer to the website: [www.sosei.com](http://www.sosei.com). Sosei acquired Arakis in August 2005.

